179 related articles for article (PubMed ID: 20920993)
1. The insulin-like growth factor signaling pathway as a target for treatment of colorectal carcinoma.
Ewing GP; Goff LW
Clin Colorectal Cancer; 2010 Oct; 9(4):219-23. PubMed ID: 20920993
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway--therapeutic perspectives in cancer.
Tao Y; Pinzi V; Bourhis J; Deutsch E
Nat Clin Pract Oncol; 2007 Oct; 4(10):591-602. PubMed ID: 17898809
[TBL] [Abstract][Full Text] [Related]
3. Insulin-Like Growth Factor (IGF) family and prostate cancer.
Gennigens C; Menetrier-Caux C; Droz JP
Crit Rev Oncol Hematol; 2006 May; 58(2):124-45. PubMed ID: 16387509
[TBL] [Abstract][Full Text] [Related]
4. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
Ozkan EE
Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
[TBL] [Abstract][Full Text] [Related]
5. Targeting insulin-like growth factor in breast cancer therapeutics.
Karamouzis MV; Papavassiliou AG
Crit Rev Oncol Hematol; 2012 Oct; 84(1):8-17. PubMed ID: 22424863
[TBL] [Abstract][Full Text] [Related]
6. Targeting the insulin-like growth factor network in cancer therapy.
Heidegger I; Pircher A; Klocker H; Massoner P
Cancer Biol Ther; 2011 Apr; 11(8):701-7. PubMed ID: 21311212
[TBL] [Abstract][Full Text] [Related]
7. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
[TBL] [Abstract][Full Text] [Related]
8. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
[TBL] [Abstract][Full Text] [Related]
9. The insulin-like growth factor (IGF) axis as an anticancer target in prostate cancer.
Heidegger I; Massoner P; Sampson N; Klocker H
Cancer Lett; 2015 Oct; 367(2):113-21. PubMed ID: 26231734
[TBL] [Abstract][Full Text] [Related]
10. Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer.
Hofmann F; García-Echeverría C
Drug Discov Today; 2005 Aug; 10(15):1041-7. PubMed ID: 16055020
[TBL] [Abstract][Full Text] [Related]
11. The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer.
Ryan PD; Goss PE
Oncologist; 2008 Jan; 13(1):16-24. PubMed ID: 18245009
[TBL] [Abstract][Full Text] [Related]
12. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
Cunningham MP; Thomas H; Marks C; Green M; Fan Z; Modjtahedi H
Int J Oncol; 2008 Nov; 33(5):1107-13. PubMed ID: 18949375
[TBL] [Abstract][Full Text] [Related]
13. State of the art and future perspectives for the use of insulin-like growth factor receptor 1 (IGF-1R) targeted treatment strategies in solid tumors.
Scartozzi M; Bianconi M; Maccaroni E; Giampieri R; Del Prete M; Berardi R; Cascinu S
Discov Med; 2011 Feb; 11(57):144-53. PubMed ID: 21356169
[TBL] [Abstract][Full Text] [Related]
14. The type 1 insulin-like growth factor receptor signalling system and targeted tyrosine kinase inhibition in cancer.
Haisa M
J Int Med Res; 2013 Apr; 41(2):253-64. PubMed ID: 23569026
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer.
Hopfner M; Sutter AP; Huether A; Baradari V; Scherubl H
World J Gastroenterol; 2006 Sep; 12(35):5635-43. PubMed ID: 17007015
[TBL] [Abstract][Full Text] [Related]
16. Specific targeting of insulin-like growth factor 1 receptor signaling in human estrogen dependent breast cancer cell by a novel tyrosine-based benzoxazepine derivative.
Chakravarti B; Siddiqui JA; Dwivedi SK; Deshpande S; Samanta K; Bhatta RS; Panda G; Prabhakar YS; Konwar R; Sanyal S; Chattopadhyay N
Mol Cell Endocrinol; 2011 May; 338(1-2):68-78. PubMed ID: 21457754
[TBL] [Abstract][Full Text] [Related]
17. Targeting insulin-like growth factor 1 receptor in sarcomas.
Scotlandi K; Picci P
Curr Opin Oncol; 2008 Jul; 20(4):419-27. PubMed ID: 18525338
[TBL] [Abstract][Full Text] [Related]
18. Novel targets for anticancer treatment development in colorectal cancer.
Macarulla T; Ramos FJ; Capdevila J; Saura C; Tabernero J
Clin Colorectal Cancer; 2006 Nov; 6(4):265-72. PubMed ID: 17241511
[TBL] [Abstract][Full Text] [Related]
19. The insulin-like growth factor 1 receptor in cancer: old focus, new future.
Hartog H; Wesseling J; Boezen HM; van der Graaf WT
Eur J Cancer; 2007 Sep; 43(13):1895-904. PubMed ID: 17624760
[TBL] [Abstract][Full Text] [Related]
20. Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade.
Iams WT; Lovly CM
Clin Cancer Res; 2015 Oct; 21(19):4270-7. PubMed ID: 26429980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
